Last updated: March 2026
PEG-MGF is the PEGylated form of Mechano Growth Factor — a splice variant of IGF-1 naturally expressed in mechanically stressed muscle. Where IGF-1 drives systemic anabolism, MGF specifically activates quiescent muscle satellite cells to proliferate and fuse with damaged fibers. PEGylation converts a tissue-local signal into a systemically injectable research compound.
When a muscle fiber is mechanically stressed, the IGF-1 gene is alternatively spliced to produce MGF in addition to IGF-1. The MGF E-domain is unique — it doesn't activate the classical IGF-1 receptor but instead signals through a separate receptor to awaken muscle satellite cells that normally remain dormant between training sessions.
The IGF-1 gene produces multiple isoforms through alternative splicing. Under mechanical load and micro-damage, muscle tissue preferentially produces MGF via a frameshift in exon 5 that creates a unique 24 amino acid E-domain. This E-domain is the functional differentiator — it's absent from systemic IGF-1 and specifically targets muscle regeneration machinery.
Muscle satellite cells (MuSCs) are adult stem cells that lie quiescent between the sarcolemma and basal lamina of muscle fibers. Normally inactive, they're awakened by mechanical damage signals. MGF's E-domain activates MuSCs to exit quiescence, proliferate, and ultimately fuse with damaged myofibers or form new myotubes — the cellular basis of hypertrophy and repair.
Native MGF has a plasma half-life of ~minutes due to rapid proteolytic degradation. Conjugating polyethylene glycol (PEG) chains to the peptide sterically shields it from enzymes, extending half-life to several days. This enables subcutaneous or intramuscular injection as a research protocol, though it fundamentally changes the pharmacokinetics from the naturally local tissue signal.
Research protocols inject PEG-MGF immediately post-workout while muscles are perfused and satellite cells are naturally responsive to damage signals. The rationale is to amplify the natural MGF signal that exercise produces. In animal studies, exogenous MGF increased muscle mass beyond exercise-only controls. All muscle-specific human data remains extrapolated from animal work.
Animal model studies and cell culture data. No human clinical trial data for MGF as a performance compound exists. All evidence labeled accordingly.
Research supplies for PEG-MGF injection protocols.
Dosing schedules, interaction warnings, and cycle protocols for 50+ compounds — all in one place.
This page is for educational and research purposes only. PEG-MGF is not approved for human use. Evidence cited is from cell culture and animal studies. No human clinical trial data exists for performance applications. Consult a qualified physician before considering any peptide compound.